Cybin Inc. moved to add flexible funding on December 30, launching an at-the-market equity program that would allow sales of up to US$100 million in common shares over time. The issuer said the facility is qualified by a prospectus supplement dated December 30 to its short form base shelf and can be used on Cboe Canada, U.S. exchanges, or other marketplaces at prevailing prices.
An at-the-market, or ATM, program lets a company sell small amounts of equity into the market, when conditions suit, instead of doing a single, fixed‑price deal. Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald & Co. are acting as agents under the distribution agreement, according to the news release. Cybin noted the ATM is one option on top of other financing tools. Investors will watch the pace and location of any sales.
Terms, timing and channels
Cybin framed the ATM as an on‑ramp rather than an obligation to issue stock. “The Company is not obligated to make any sales of Shares under the ATM Program,” the issuer said in its December 30 announcement, adding that volume and timing “will be determined in Cybin’s sole discretion.”
The program runs alongside a refreshed shelf, with the supplement dated December 30 referencing the new document. Under that same announcement, Cybin also set out that the facility “will be effective until the earlier of the issuance and sale of all of the Shares issuable pursuant to the ATM Program and October 17, 2027.”
The ATM can be used on Cboe Canada and U.S. exchanges, which gives the issuer flexibility across markets. Cybin said any proceeds are earmarked for growth and working capital. The detailed terms are contained in the company’s December 30 news release.
Shelf capacity and recent financing
The move comes after Cybin lifted its base shelf capacity this month. On December 19, the issuer filed an amendment to its short form base shelf prospectus to increase the aggregate amount available to C$1.7 billion during the 25‑month period ending October 17, 2027. The filing, made under the multijurisdictional disclosure system, sets the framework for offerings in Canada and the United States and reflects a larger menu of potential securities.
The amendment is posted on the U.S. Securities and Exchange Commission’s site under Form F‑10 and specifies the higher limit for common shares, warrants, units, debt securities and subscription receipts, giving Cybin room to manoeuvre as markets shift. The company’s shelf mechanics reinforce that the ATM is one path within a broader capital plan.
Cybin has used ATMs before. In February 2025, the issuer qualified a US$100 million ATM under its then‑effective base shelf and entered a distribution agreement with the same agents, Cantor Fitzgerald’s Canadian and U.S. units.
That program was effective until September 17, 2025, when the prior shelf expired, and Cybin disclosed modest usage in the fiscal period. The filing shows the issuer’s preference for incremental issuance when liquidity allows, rather than large one‑day discounts.
Capital backdrop and what to watch
Beyond the ATM, Cybin tapped larger blocks of capital this fall. On October 31, the issuer closed a US$175 million registered direct financing with a roster of specialist biotech investors, with disclosed uses including debt repayment and pipeline funding. That raise signalled appetite to fund late‑stage programs while balancing the cost of capital.
The mix of a big direct placement and a new ATM suggests Cybin wants both runway and flexibility as clinical and regulatory milestones approach. Secondary-market reaction will hinge on how often the ATM is used and at what price levels.
“The volume and timing of distributions under the ATM Program, if any, will be determined in Cybin’s sole discretion,” the issuer said in the December 30 release, which underscores control over potential dilution.
